Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 24

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 24
---
 result in resales
of our Common Stock by our current stockholders concerned about the potential ownership dilution of their holdings. Furthermore, in the
future, we may issue additional shares of Common Stock or other equity or debt securities exercisable or convertible into Common Stock.
Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.

Investors who buy shares at different times will likely pay different prices.

Investors who purchase shares in this offering at
different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their investment
results.

This offering may cause the trading price of our Common Stock to decrease.

The price per share of our Common Stock, together
with the number of shares of Common Stock we propose to issue upon exercise of the Common Warrants and ultimately will issue if this offering
is completed, may result in an immediate decrease in the market price of our Common Stock. This decrease may continue after the completion
of this offering. Sales of substantial amounts of our Common Stock in the public market, or the perception that such sales might occur,
could adversely affect the market price of our Common Stock.

Our management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.

We have not designated any portion of the net proceeds
from the exercise of Common Warrants to be used for any particular purpose. Accordingly, our management will have broad discretion as
to the use of the net proceeds and you will be relying on the judgment of our management with regard to the use of these net proceeds,
and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that, pending their use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for our
company. Our management’s judgment may not result in positive returns on your investment and you will not have the opportunity to
evaluate the economic, financial or other information upon which our management bases its decisions.

Risks Related to our Diagnostic Product

Until we secure FDA clearance for CyPath ®Lung as a Class II in vitro diagnostic, we may encounter physicians who will not order an LDT.

In order to market our CyPath Lung
as an IVD medical device, we must receive de novo classification from the FDA as a Class II in vitro diagnostic.